Humana Inc. $HUM Stock Holdings Boosted by Willner & Heller LLC

Willner & Heller LLC boosted its stake in Humana Inc. (NYSE:HUM) by 23.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,180 shares of the insurance provider’s stock after buying an additional 415 shares during the period. Willner & Heller LLC’s holdings in Humana were worth $533,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cary Street Partners Investment Advisory LLC boosted its position in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Riverview Trust Co purchased a new stake in Humana during the first quarter valued at about $34,000. Garde Capital Inc. purchased a new stake in Humana during the first quarter valued at about $36,000. Zions Bancorporation National Association UT purchased a new stake in Humana during the first quarter valued at about $37,000. Finally, Ransom Advisory Ltd purchased a new stake in shares of Humana in the first quarter worth approximately $66,000. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 10.7%

Shares of Humana stock opened at $284.00 on Friday. The company’s fifty day simple moving average is $274.76 and its 200-day simple moving average is $257.42. The company has a market cap of $34.16 billion, a price-to-earnings ratio of 21.80, a PEG ratio of 1.51 and a beta of 0.42. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. Humana’s payout ratio is currently 27.17%.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HUM shares. Mizuho set a $300.00 price objective on shares of Humana in a research report on Friday. Wall Street Zen downgraded Humana from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Morgan Stanley dropped their price target on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 31st. Piper Sandler dropped their price target on shares of Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research report on Thursday, July 31st. Finally, Bank of America lifted their price target on shares of Humana from $285.00 to $312.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Seven equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Humana currently has an average rating of “Hold” and a consensus target price of $291.21.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.